American Heart Association Announces Creation of Cardiogenic Shock Registry

Article

Announced on October 19, the American Heart Association's Cardiogenic Shock Registry powered by Get With The Guidelines was created with the intent of providing researchers with access to real-time data related to care and outcomes of patients with cardiogenic shock in the US to help improve management.

Mitchell Krucoff, MD

Mitchell Krucoff, MD

The American Heart Association (AHA) has announced the launch of a new registry aiming to capture data related to management and outcomes of cariogenic shock from acute care centers across the US.

Announced on October 19, the Cardiogenic Shock Registry powered by Get With The Guidelines® is a no-cost registry aimed at collecting and disseminating real-time data to improve quality of care for patients with cardiogenic shock symptoms by building on more than 2 decades of experience from the AHA’s Get With The Guidelines platform.

“To understand how to improve care for cardiogenic shock patients, we first need a clearer view of the landscape of existing treatment practices for cardiogenic shock in U.S.-based acute care settings,” said Mitchell Krucoff, MD, volunteer expert for the American Heart Association and professor of medicine at Duke University, in a statement. "No organization is better positioned to advance this critical public health question than the American Heart Association, with already established networks of sites entering data on heart failure, acute cardiac syndromes, cardiac arrest and COVID—all of which involve patients at risk of progressing to cardiogenic shock.”

Launched less than a year after the Society for Cardiovascular Angiography and Interventions released their updated SHOCK stages classifications, which were endorsed by the AHA, the AHA’s new registry represent the latest in a growing emphasis from the cardiovascular community to improve management of this patient population. National level aggregated, deidentified data collected in the registry will be made available to researchers through the AHA’s Precision Medicine Platform, which is a cloud-computing platform powered by Amazon Web Services created to help facilitate research.

Supported by funding from Abbott and Getinge, the registry was founded with 5 core scientific aims highlighted on the AHA on the Cardiogenic Shock Registry page:

  • Study cardiogenic shock, including diagnosis, treatment, and outcomes among patients in real-world acute care clinical settings throughout the U.S.
  • Provide high-quality evidence that helps inform clinicians, researchers, federal agencies, industry and other healthcare stakeholders on best practices for treating cardiogenic shock patients.
  • Develop streamlined longitudinal research infrastructure for pragmatic clinical trials and other translational, clinical, and implementation science.
  • Create and pilot evidence-based performance metrics for national benchmarking.
  • Promote systems-of-care metrics for cardiogenic shock patients that strive for health equity.

"The new Cardiogenic Shock Registry will leverage the unparalleled reach of the American Heart Association in a unique collaboration between academic clinicians and researchers, federal agencies and funding supporters’ experts to provide high-quality evidence and promote best practices for the treatment of patients with cardiogenic shock,” said David Morrow, MD, MPH, volunteer expert for the American Heart Association and professor of medicine, Harvard Medical School, in the aforementioned statement.

Related Videos
Kelley Branch, MD, MS | Credit: University of Washington Medicine
David Berg, MD, MPH | Credit: Brigham and Women's
HCPLive Five at ACC 2024 | Image Credit: HCPLive
Ankeet Bhatt, MD, MBA | Credit: X.com
Ankeet Bhatt, MD, MBA | Credit: X.com
Sara Saberi, MD | Credit: University of Michigan
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
Albert Foa, MD, PhD | Credit: HCPLive
Veraprapas Kittipibul, MD | Credit: X.com
Heart Failure stock imagery. | Credit: Fotolia
© 2024 MJH Life Sciences

All rights reserved.